Pharma

Your Article Summary

See Latest Articles

Allos Therapeutics Announces FDA Advisory Committee Recommends Accelerated Approval of FOLOTYN(TM) for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
Allos Therapeutics, 09/28/09

Allos Therapeutics, Inc. announced that the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee voted 10–4 that the response rate and duration of response observed with FOLOTYNTM are reasonably likely to predict clinical benefit in patients with relapsed or refractory peripheral T–cell lymphoma. PTCL comprises a biologically diverse group of aggressive blood cancers that has a worse prognosis than most other types of lymphoma, including B–cell lymphoma. If approved, FOLOTYN would be the first drug approved by the FDA for the treatment of relapsed or refractory PTCL.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Novartis gains rights to two oral targeted investigational therapies focusing on patients with life-threatening blood disorders and cancers
Novartis, 11/30/09

Major European regulatory milestone in cardiovascular protection for Micardis : Now approved by the European Commission to reduce the risk of cardiovascular (CV) morbidity in high CV risk patients
Boehringer Ingelheim, 11/30/09

Human genome sciences submits biologics license application to fda for zalbin
Human Genome Sciences, 11/30/09

 See all of Drug/Product Approvals